Format

Send to

Choose Destination
Ann Oncol. 2011 Jun;22(6):1367-73. doi: 10.1093/annonc/mdq604. Epub 2011 Jan 7.

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. jang@partners.org

Abstract

BACKGROUND:

Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of esophageal and gastric carcinomas. Although previous studies have examined tyrosine kinase inhibitors of EGFR, there remains limited data regarding the role of EGFR-directed monoclonal antibody therapy in these malignancies. We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against EGFR, in patients with unresectable or metastatic esophageal or gastric adenocarcinoma.

PATIENTS AND METHODS:

Thirty-five patients with previously treated metastatic esophageal or gastric adenocarcinoma were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). Patients were followed for toxicity, treatment response, and survival.

RESULTS:

Treatment with cetuximab was well tolerated; no patients were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) patients had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively.

CONCLUSION:

Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Ongoing studies of EGFR inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and gastric cancer.

PMID:
21217058
PMCID:
PMC3493129
DOI:
10.1093/annonc/mdq604
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center